This trial is active, not recruiting.

Condition sleep apnea, obstructive
Treatment aspire medical advance system
Sponsor Aspire Medical
Start date April 2007
End date October 2007
Trial size 42 participants
Trial identifier NCT00467324, TAS 002


The objective of the study is to assess the effectiveness of the Aspire Medical Advance System in obstructive sleep apnea by demonstrating a statistically significant mean reduction in the apnea-hypopnea index (AHI) from baseline to 6 months, measured by polysomnography (PSG).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Apnea hypopnea index measured with polysomnography 6 months after implantation of the Advance System
time frame: 6 months

Secondary Outcomes

Epworth Sleepiness Scale (ESS) measured at 6 months post-implantation
time frame: 6 months
Functional Outcomes of Sleep Questionnaire (FOSQ) measured at 6 months post-implantation
time frame: 6 months
Safety: assessment of all device-related and procedure related adverse events and their seriousness
time frame: 6 months

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria

  • Previously diagnosed or screened with moderate to severe sleep apnea who have an AHI of between 15 and 60
  • Age between 18 and 65
  • Body mass index (BMI) </= 32
  • Patient has been offered CPAP and has refused or failed to continue CPAP treatment
  • Identified evidence of airway collapse at the base of the tongue
  • Signed informed consent

Exclusion Criteria

  • Prior OSA surgery except tonsillectomy, adenoidectomy, and nasal surgery
  • Enlarged tonsils (3+ and 4+)
  • Anatomy unable to accommodate the implant
  • Severe mandibular deficiency/retrognathia
  • Significant rhinitis/nasal obstruction
  • Unable and/or not willing to comply with treatment follow-up requirements
  • Pregnancy (female subjects of childbearing age mus have a negative pregnancy test prior to enrollment and should maintain adequate contraception during the study) or breastfeeding
  • Active systemic infection
  • Allergy to latex or any medication used during implantation
  • Previous history of neck or upper respiratory tract cancer
  • History of radiation therapy to neck or upper respiratory tract
  • Dysphagia
  • History of major cardiovascular disorders including MI, angina, uncontrolled hypertension, and CHF
  • Major pulmonary disorders including COPD and uncontrolled asthma
  • Patient is suffering from untreated/inadequately treated major depression, as determined by history
  • History of falling asleep driving or motor vehicle accident secondary to excessive sleepiness
  • Anesthesia risk group ASA Class IV or V
  • Other medical, social or psychological problems that, in the opinion of the investigator, could complicate the procedure and/or recovery from this treatment or could complicate the procedures and evaluations pre- and post-treatment
  • Enrollment in another pharmacological or medical device study

Additional Information

Official title The Advance Trial. Tongue Advancement for Obstructive Sleep Apnea: An Evaluation of the Aspire Medical Advance System
Principal investigator Tucker Woodson, MD
Description Obstructive sleep apnea (OSA) is a major health problem in the United States and can result in excessive daytime sleepiness and cardiovascular problems. The primary treatment for OSA today is continuous positive airway pressure (CPAP). Many patients however are unable to tolerate sleeping with a CPAP machine. Surgery is one of the main treatment options available today to these CPAP-intolerant patients. However, current methods of sleep surgery are painful, morbid, and/or lack decent effectiveness. This trial will measure the effectiveness of the Advance System, an implantable medical device to treat OSA. In the trial, patients who meet the study entry criteria receive a baseline sleep study (PSG). The Advance System is then implanted and 6 months after implantation, another PSG is performed. The trial will compare the baseline and the 6 month apnea-hypopnea indices
Trial information was received from ClinicalTrials.gov and was last updated in October 2008.
Information provided to ClinicalTrials.gov by Aspire Medical.